109 related articles for article (PubMed ID: 6789633)
21. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
22. BCG immunostimulation in primary pulmonary cancer (a clinical, immunological and radiological study).
Dénes L; Büttner K; Galambos G; Krasznai G
Dev Biol Stand; 1986; 58 ( Pt A)():425-32. PubMed ID: 3297874
[TBL] [Abstract][Full Text] [Related]
23. BCG, levamisole and transfer factor in the treatment of cancer.
Spitler LE
Prog Exp Tumor Res; 1980; 25():178-92. PubMed ID: 6986631
[No Abstract] [Full Text] [Related]
24. Immunotherapy of bladder cancer with intralesional injection with BCG.
Calsini P; Scapicchi G; Gazzarini O; Melone F; Aulisi A; Pellegrini G; Fabris N; Provinciali M
J Exp Pathol; 1987; 3(4):579-86. PubMed ID: 3454805
[TBL] [Abstract][Full Text] [Related]
25. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy of cancer patients with Bacillus Calmette-Guérin: summary of four years of experience in Japan.
Torisu M; Fukawa M; Nishimura M; Harasaki H; Kai S; Tanaka J
Ann N Y Acad Sci; 1976; 277(00):160-86. PubMed ID: 1069547
[TBL] [Abstract][Full Text] [Related]
27. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
[TBL] [Abstract][Full Text] [Related]
28. Combination radiofrequency ablation and local injection of the immunostimulant bacillus Calmette-Guérin induces antitumor immunity in the lung and at a distant VX2 tumor in a rabbit model.
Hamamoto S; Okuma T; Yamamoto A; Kageyama K; Ueki A; Matsuoka T; Miki Y
J Vasc Interv Radiol; 2015 Feb; 26(2):271-8. PubMed ID: 25443457
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
[TBL] [Abstract][Full Text] [Related]
30. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
31. The phase II evaluation of Bacillus Calmette-Guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma.
Laucius JF; Patel YA; Lusch CJ; Koons LS; Bellet RE; Mastrangelo MJ
Med Pediatr Oncol; 1977; 3(3):237-42. PubMed ID: 618010
[TBL] [Abstract][Full Text] [Related]
32. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
33. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy plus immunotherapy for patients with primary and metastatic brain tumors.
Knerich R; Robustelli della Cuna G; Butti G; Pavesi L; Adinolfi D; Preti P; Locatelli D
J Neurosurg Sci; 1985; 29(1):19-24. PubMed ID: 3906050
[TBL] [Abstract][Full Text] [Related]
35. Intrapleural BCG in postsurgical stage I non-small cell lung cancer.
Macchiarini P; Mussi A; Angeletti CA
Anticancer Res; 1989; 9(2):391-3. PubMed ID: 2546484
[TBL] [Abstract][Full Text] [Related]
36. Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.
Weiss BE; Pietzak EJ; Wein AJ; Malkowicz SB; Guzzo TJ
Can J Urol; 2015 Aug; 22(4):7876-81. PubMed ID: 26267025
[TBL] [Abstract][Full Text] [Related]
37. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
38. Effect of systemic administration of BCG cell walls on bronchogenic carcinoma in hamsters.
Zwilling BS; Springer ST; Kaufman DG
J Natl Cancer Inst; 1977 May; 58(5):1473-7. PubMed ID: 323508
[TBL] [Abstract][Full Text] [Related]
39. Regional immunotherapy in resectable squamous cell lung carcinoma. Analysis of a randomized study.
Roeslin N; Lang JM; Morand G; Wihlm JM; Witz JP
Cancer Immunol Immunother; 1982; 13(3):174-5. PubMed ID: 6925982
[TBL] [Abstract][Full Text] [Related]
40. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
